BIOMAT Database Logo BIOMAT Database Logo

Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease. 2013

Paulo Salgueiro, and Paula Lago, and Isabel Pedroto

UI MeSH Term Description Entries
D008297 Male Males
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068879 Adalimumab A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. Adalimumab-adbm,Adalimumab-atto,Amjevita,Cyltezo,D2E7 Antibody,Humira,Antibody, D2E7
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
December 2017, Internal medicine journal,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease.
April 2015, World journal of gastroenterology,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Improving access for anti-tumour necrosis factor-a therapy in inflammatory bowel disease.
November 2010, The Medical journal of Australia,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease.
January 2009, British medical bulletin,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
May 2012, Alimentary pharmacology & therapeutics,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
March 2015, Danish medical journal,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
September 2018, Digestive diseases and sciences,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
May 2015, Journal of Crohn's & colitis,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.
February 2010, Internal medicine journal,
Paulo Salgueiro, and Paula Lago, and Isabel Pedroto
Inflammatory skin eruptions induced by anti-tumour necrosis factor-α therapy differ undeniably from psoriasis or eczema.
May 2018, The British journal of dermatology,
Copied contents to your clipboard!